President has served as a reviewer for the ZRG1 IMST-L (55) ‘Innovative Research in Cancer Nanotechnology’ (R01) Study Section for the NIH

PDX Pharma’s President/CEO, Dr. Wassana Yantasee, has served as a reviewer for the ZRG1 IMST-L (55)  PAR-17-240 ‘Innovative Research in Cancer Nanotechnology (IRCN)’ (R01) Study Section for the National Institute of Health (NIH), held in Washington DC on March 29, 2018.